在试验背景下,R21/Matrix-M疟疾疫苗与现有的疟疾干预措施相结合的可接受性
Halimatou Diawara1, Jane Grant2, Alassane Dicko1
1Malaria Research and Training Centre, University of Sciences Techniques and Technologies of Bamako, Bamako, Mali.
BMJ global health
|February 3, 2025
概括
马里的社区可以接受R21/Matrix-M疟疾疫苗. 护理人员和社区信任疫苗,但需要实施研究,以确保它补充其他疟疾预防方法.
科学领域:
- 全球健康 全球健康
- 疫苗学 疫苗学 疫苗学
- 预防疟疾 预防疟疾
背景情况:
- 疟疾疫苗R21/Matrix-M在III期试验中显示出高效,并被世界卫生组织推.
- 在撒哈拉以南非洲大规模部署即将到来.
- 了解社区和护理人员的接受对于成功的整合至关重要.
研究的目的:
- 评估护理人员和社区对R21/Matrix-M疫苗的接受度.
- 评估其与马里现有的疟疾干预措施一起的接受度.
- 为了告知疫苗的规模部署.
主要方法:
- 通过33次深入访谈 (IDI),12次焦点小组讨论 (FGD) 和45次与护理人员的退出访谈进行定性数据收集.
- 18个IDI和8个FGD与社区成员,13个IDI与卫生工作者,8个IDI与试验人员.
- 使用Sekhon关于可接受性的理论框架进行分析.
主要成果:
- 由疟疾负担,感知疫苗有效性和对试验的信任驱动的高可接受性.
- 一些护理人员认为季节性疟疾化学预防 (SMC) 的重要性下降.
- 其他人则将R21/Matrix-M,SMC和用杀虫剂处理的网视为补充干预措施.
结论:
- 马里的护理人员和社区认为R21/Matrix-M疫苗是可以接受的.
- 实施研究至关重要,以确保R21/Matrix-M与SMC和其他干预措施的共同覆盖.
- 这对于在疫苗扩展期间成功控制疟疾至关重要.
相关概念视频
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...